BioCentury | Aug 6, 2020
Emerging Company Profile

Off-the-shelf cell therapy pioneers, Versant launch Matterhorn to tackle broad range of cancers

...antigen and HLA combination on the surface of tumor cells. But in most cases, the HLA...
...1 issued covering the use of MR1-restricted T cells in cancer immunotherapy Targets HLA - Human leukocyte antigen...
...T cell receptor Danielle Golovin, Staff Writer Versant Ventures Ervaxx Ltd. Cardiff University Major histocompatibility complex, class I-related (MR1) (HLALS) Human leukocyte antigen (HLA) T...
BioCentury | Aug 1, 2020
Translation in Brief

TScan identifies CD8+ T cell COVID-19 epitopes, plus T3 gears up for Phase I of bacterial cancer therapy, a wearable device to monitor PK and a COVID-19 vaccine

...29 CD8 + T cell epitopes shared across the six most prevalent HLA types. Each HLA...
...T cells that recognized at least one of the three most dominant epitopes for each HLA...
...SARS-CoV-2 had no detectable virus in the lungs four days after infection. Targets HLA - Human leukocyte antigen...
BioCentury | Jul 28, 2020
Product Development

TCR2 gains on first signs of cell therapy efficacy in solid tumors

...receptor, which allows the cells to be programmed against any cell surface antigen without the HLA...
...may translate to higher efficacy than engineered TCR T cell therapies, as tumors often downregulate HLA...
...to evade immune detection, and surface antigens are often present at a higher density than HLA-presented...
BioCentury | Jul 21, 2020
Deals

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

...a chance to gain full ownership of TTX-080, a first-in-class antibody that inhibits immune checkpoint HLA-G...
...nine employees and will be funded with an undisclosed amount of cash from Tizona. Targets HLA-G...
...class I G Paul Bonanos, Associate Editor Tizona Therapeutics Inc. Gilead Sciences Inc. Major histocompatibility complex class I G (HLA-G) TTX-080...
BioCentury | Jun 23, 2020
Tools & Techniques

AI tools against COVID-19: a view from where the rubber hits the road

...the genetic diversity of where we want to be applying this?” he said, noting that HLA...
...the pandemic, and I hope some of that spirit survives,” said Robins. Targets HLA - Human leukocyte antigen...
BioCentury | May 16, 2020
Product Development

A guide to COVID-19 preclinical vaccine modalities

...presentation by endogenous APCs. A "decoy cell" vaccine from Sorrento Therapeutics Inc. (NASDAQ:SRNE) uses non-replicating, HLA-negative...
...the coronavirus crisis can be found in BioCentury’s COVID-19 Resource Center . Targets HLA - Human leukocyte antigen...
BioCentury | May 12, 2020
Product Development

Vaccine prospects for COVID-19: learnings from a 40-year biotech journey that’s still in progress

...more new technology, including single cell sequencing platforms, to uncover the peptides responsible for both HLA...
BioCentury | May 12, 2020
Product Development

May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX

...and the donor-derived modified immune cell (MIC) therapy, there were no rejection episodes, donor-specific human leukocyte antigen (HLA...
BioCentury | May 9, 2020
Product Development

A guide to COVID-19 vaccine modalities in the clinic

...Writer Transmembrane protease serine 2 (TMPRSS2) SARS-CoV-2 spike protein (SARS-CoV-2 S) Angiotensin-converting enzyme 2 (ACE2) Major histocompatibility complex (MHC) Human leukocyte antigen (HLA) COVID-19 cov19count cov19sci cov19count cov19sci...
BioCentury | Mar 30, 2020
Finance

ElevateBio raises $170M, plans additions to portfolio with six clinical programs by 2021

...round announced in May 2019 (see “Creating A Portfolio With $150M” ). Targets HMHA1 (HA-1; HLA-HA1...
Items per page:
1 - 10 of 579